CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Regulation FD Disclosure

On December 9, 2017, Catalyst Biosciences, Inc. delivered a presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. A copy of the presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

On December 11, 2017, Catalyst Biosciences, Inc. issued a press release announcing interim Phase 1/2 data on its subcutaneously administered, prophylactic Factor IX variant CB 2679d/ISU304 that were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA, on December 9, 2017.

Acopy of the press release announcing the interim Phase 1/2 data is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

(d) Exhibits.

CATALYST BIOSCIENCES, INC. ExhibitEX-99.1 2 cbio-ex991_92.htm EX-99.1 cbio-ex991_92.htm Exhibit 99.1   Phase1/2 Trial of Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics and Activity Chur Woo You,…To view the full exhibit click here
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.